Impact Biomedical (IBO) Gross Margin (2025 - 2026)
Impact Biomedical's Gross Margin came in at 66.67% for Q2 2026, down 19.05 percentage points from 85.71% a year earlier.
Powered by 
Analysis
Impact Biomedical (IBO) Gross Margin (2025 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 85.78% |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 68.12% |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | 74.74% |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | 73.54% |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 78.02% |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 83.60% |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 72.04% |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | 79.76% |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | 72.78% |
| 10 | Impact Biomedical | 409.72 Mn | 412.92 Mn | 2,000.00 | 66.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.67% |
| Sep 30, 2025 | 94.44% |
| Jun 30, 2025 | 85.71% |
API Access
Impact Biomedical Gross Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gross-margin&ticker=IBO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gross-margin", "ticker": "IBO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gross-margin&ticker=IBO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();